Freezor modification
This article was originally published in The Gray Sheet
Executive Summary
CryoCath's FreezorXtra, the larger version of the Freezor cryoablation catheter, is now available to a limited number of U.S. electrophysiologists after earning 510(k) clearance for epicardial ablation, the Montreal company announces May 8. Until the company's clinical advisory board completes a comprehensive dissemination plan later this year, the device will be targeted to operators familiar with the epicardial arrhythmia ablation technique pioneered by Eduardo Sosa, MD, University of Sao Paulo. On April 22, Freezor was approved for treating atrioventricular node re-entry tachycardia (1"The Gray Sheet" May 5, 2003, In Brief)...
You may also be interested in...
CryoCath clarification
FDA-approved labeling for CryoCath's Freezor ablation catheter, PMA-approved April 22, includes directions for performing cryomapping prior to cryoablation of atrioventricular node re-entry tachycardia. However, the Freezor's instructions for use do not list cryomapping as a specific indication, as was reported in "The Gray Sheet" (April 28, p. 5)...
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: